Friday, December 09, 2022 10:32:27 AM
It wants $90.
I got a sell order in @88, but think it will continue up.
Gilead is moving away from HIV and more into this cancer thingy.
That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too
Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
I got a sell order in @88, but think it will continue up.
Gilead is moving away from HIV and more into this cancer thingy.
That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too
Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
Recent GILD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 12:55:23 AM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 05/28/2026 12:51:00 AM
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar) • Business Wire • 05/27/2026 06:00:00 AM
- FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) • Business Wire • 05/22/2026 06:00:00 PM
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors • Business Wire • 05/22/2026 11:47:00 AM
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology • Business Wire • 05/21/2026 09:00:00 PM
- Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio • Business Wire • 05/21/2026 01:30:00 PM
- Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease • Business Wire • 05/21/2026 07:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:15:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:50:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:45:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 08:15:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:09:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:07:18 PM
- Gilead Prices $3 Billion of Senior Unsecured Notes • Business Wire • 05/15/2026 01:21:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/14/2026 09:11:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/14/2026 12:46:00 PM
- Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 • Business Wire • 05/13/2026 12:30:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/08/2026 09:00:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 09:13:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 09:12:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:03:01 PM
- Gilead Sciences Announces First Quarter Financial Results • Business Wire • 05/07/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:40:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:36:45 PM

